Is SottoPelle FDA Approved?

Regulatory status check

Last verified: August 2026 · By The HRT Index Editorial Team · Editorial research. Not medical advice, and not medically reviewed by a clinician — see our medical review policy.

Is SottoPelle FDA approved? No. The SottoPelle Method is not an FDA-approved drug, and the custom-compounded estradiol and/or testosterone pellets used through SottoPelle-certified clinics are not FDA-approved finished products. A 503B facility may be FDA-registered and inspected, but registration is not product approval. Testopel is a separate FDA-approved testosterone pellet labeled for males.^[1][2][7]

Best for you if	A clinic, friend, or website used “FDA approved,” “FDA regulated,” “FDA certified 503B,” “approved ingredients,” or “same as Testopel,” and you want to know what those words actually prove before you pay.
Not for you if	You need a personal medical clearance, diagnosis, or urgent advice about symptoms after an insertion. Those decisions belong with a licensed clinician who knows your history.
The deciding evidence	The exact product label, hormone and dose, legal name and address of the compounder, lot number, and intended use — not the SottoPelle name alone.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

---

Does SottoPelle itself claim FDA approval?

No — and here is the part almost nobody explains. On August 25, 2026, SottoPelle’s current patient page, provider-training page, pricing page, and Standard of Care PDF did not call the finished pellets FDA approved. But an older SottoPelle-domain article uses the inaccurate phrase “FDA certified 503B facility,” so the clean finding is not that SottoPelle never uses FDA language — it is that registration language has been blurred without establishing product approval.^{[9][10][12][13]}

The strongest “SottoPelle is FDA approved” claims we found came from independent clinics using the brand, not from an FDA approval record.

Nothing about your body changes the regulatory answer. It is no for everyone. Three things change what that answer means for your decision:

• Whether you have a uterus. Systemic estrogen raises a separate endometrial-protection question. A woman with a uterus needs a clear clinician-led plan for progestogen use and unexpected bleeding.^[17]
• Which pharmacy made your exact pellet. SottoPelle tells providers they have the “freedom to select your pellet provider,” so the brand does not identify one universal manufacturer, formulation, or lot.^[10]
• Whether an FDA-approved route can meet the same clinical need. FDA-approved estradiol and progesterone products exist in multiple routes. The United States still has no FDA-approved testosterone product for women, which is a separate gap — not approval of compounded pellets.^[20][16]

The approval question is simple. The treatment decision is not.

---

What can “FDA” mean in a SottoPelle consultation?

When someone says “FDA” in a pellet consultation, the word may be attached to the method, the finished drug, the facility, an ingredient, a patent, an NDC, or Testopel. Only one row below describes an FDA-approved drug product, and it is not a SottoPelle menopause pellet.

The HRT Index FDA-status decoder — verified August 25, 2026

What “FDA” is attached to	FDA approved?	What it actually establishes	What it does not establish
The SottoPelle Method	No — it is not a drug	A branded training, dosing, certification, and support system exists	Approval of any pellet, dose, use, pharmacy, or clinic
The compounded pellet itself	No	A licensed prescriber ordered a product prepared through a compounding pathway	FDA premarket review of that finished product’s safety, effectiveness, quality, labeling, or consistency
A 503B outsourcing facility	The facility is registered; its compounded drugs are not approved	The facility registered with FDA, is subject to CGMP requirements, must report adverse events, and is placed on a risk-based inspection schedule	That every batch is FDA approved, that the facility is currently compliant, or that a past inspection guarantees today’s conditions
“FDA-regulated ingredients”	Not proof of finished-product approval	Ingredients and supply-chain activities may be subject to federal requirements	Approval of the pellet’s final formula, strength, dose, route, label, or intended use
A patent or patented dosing system	No	The patent system protects an invention	FDA review of safety, effectiveness, quality, or clinical outcomes
An NDC number or DailyMed page	Not by itself	A product-identification or labeling record exists	FDA approval; FDA says an NDC does not denote approval
Testopel	Yes — but it is a different product	A specific 75 mg testosterone pellet has an approved ANDA and current prescribing information for specified male indications	Approval of SottoPelle, compounded pellets, estradiol pellets, or testosterone-pellet use for menopausal women

Several of those labels are real. None transfers approval to the compounded pellet going under your skin.

---

What did The HRT Index actually verify?

We built this page by placing SottoPelle’s current wording beside FDA definitions, the current Testopel label, professional guidance, payer policies, and peer-reviewed pellet studies. Commercial sources support only what a company or clinic says; medical and regulatory conclusions come from primary or authoritative sources.

Read firsthand on August 25, 2026:

• SottoPelle’s current patient page, provider-training page, provider-pricing page, terms, and two-page Standard of Care PDF
• the FDA’s compounding Q&A, 503B registration Q&A, registered-outsourcing-facility directory, and NDC disclaimer
• the current Testopel prescribing information and federal Schedule III rule
• ACOG Clinical Consensus No. 6, reaffirmed in 2026
• The Menopause Society’s current patient guidance on approved and custom-compounded hormone therapy
• the FDA’s September 9, 2019 statement about 4,202 unreported adverse-event records and the 61 reports it could attribute
• the FDA’s February 12, 2026 menopause-label update and the current list of six products with revised prescribing information
• current payer policy examples showing why coverage must be checked product by product and plan by plan
• the Wheatley estradiol-implant audit and the Jiang retrospective pellet comparison
• FDA’s July 2026 and next scheduled Pharmacy Compounding Advisory Committee topics
• the August 18, 2026 Federal Register notice for the September 17 FDA workshop on testosterone use in menopausal women

What we could not verify from SottoPelle’s public materials: the legal name of the 503B facility that made the exact pellet used by every SottoPelle-certified clinic. SottoPelle’s provider materials describe supplier choice and access to multiple 503B facilities. The clinic’s written answer — plus the package label and lot record — is the reliable way to identify your manufacturer.^[10]

What we earn from this page: nothing from SottoPelle, Biote, Testopel, or any pellet clinic. The HRT Index may earn a commission from some telehealth providers reached through clearly labeled links elsewhere on the site. It did not change the regulatory answer, and no provider reviewed or approved this page. See our affiliate disclosure.

---

What does this FDA answer mean for your next step?

The FDA answer is universal, but the right next route depends on the woman. That is where a general page has to stop pretending it can prescribe from a distance.

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

---

Is SottoPelle FDA approved? The full answer

No. The custom-compounded estradiol and/or testosterone pellets used through SottoPelle-certified clinics are not FDA-approved finished drugs. FDA does not verify the safety, effectiveness, or quality of a compounded drug before it is marketed, even when the compounder is a registered 503B outsourcing facility.^[1][2]

What “not FDA approved” means

• The finished compounded pellet did not go through FDA’s new-drug approval process.
• FDA did not approve prescribing information for that exact finished product, including standardized indications, dosing, contraindications, and warnings.
• FDA did not review that finished product’s manufacturing controls through the new-drug approval process.
• An approved estradiol or testosterone product elsewhere does not approve a different route, strength, formulation, compounder, or use.
• A clinic cannot turn a compounded pellet into an approved drug by calling the ingredient “bioidentical,” “natural,” “FDA regulated,” or “the same as Testopel.”

What “not FDA approved” does not mean

• It does not automatically mean illegal. Federal law provides compounding pathways, and a licensed clinician may prescribe a compounded medication when legal requirements are met.
• It does not mean there is no oversight. State boards are the primary regulators of traditional 503A pharmacies. Registered 503B outsourcing facilities remain subject to state oversight and have direct federal obligations including CGMP, adverse-event reporting, and risk-based FDA inspection.^[1][2]
• It does not prove that every pellet is defective or that every patient will have a bad outcome. Lack of approval and proof of harm are different questions.
• It does not mean compounding has no legitimate role. Compounding can meet a real need when an approved product is not medically appropriate — for example, because of an allergy to an inactive ingredient or a needed dosage form that is not commercially available.^[1]

Here is the damaging admission the anti-pellet pages often skip: “not FDA approved” is not a verdict that every woman who chose a pellet made a foolish or reckless decision. It is a statement about what was — and was not — reviewed before the product reached her.

What SottoPelle actually is

SottoPelle is best understood as a clinician-training, certification, dosing-technology, licensing, and support system used by independent practices. Its current public pricing page sells provider education rather than a national patient treatment package.^[11]

Its provider-training page states that:

• the curriculum contains 13 required modules and two insertion videos;
• the in-person program is a full one-day course;
• the online program allows five days for completion and says it can be completed in as little as one day;
• completion produces a certificate and a SottoPelle Certified Provider designation;
• maintenance fees cover access to technology and brand licensing, including patents, intellectual property, and trademark protection; and
• certified providers have supplier choice and access to 503B outsourcing facilities.^[10]

That is a real training and commercial infrastructure. It is not drug approval, and it is not a guarantee that every independent clinic provides identical screening, dosing, informed consent, follow-up, complication management, or pricing.

SottoPelle’s own terms are unusually direct about the limit. The company says it does not verify every directory professional’s active licenses, credentials, disciplinary history, insurance coverage, price, or quality of care and does not endorse the listed clinicians.^[14]

The seal tells you which system the clinician trained in. It does not finish your vetting for you.

---

What does “FDA-registered 503B facility” actually mean?

A 503B outsourcing facility is a compounder that registered with FDA and is subject to federal requirements that do not apply in the same way to a traditional 503A pharmacy. That is meaningful, but FDA states that registration does not mean the facility is making FDA-approved drugs or is currently compliant with every requirement.^[2]

The strongest accurate version is:

A registered 503B facility adds federal manufacturing, reporting, and inspection obligations. It does not convert the compounded finished pellet into an FDA-approved drug.

Registered outsourcing facilities:

• are subject to current good manufacturing practice requirements;
• must report adverse events to FDA;
• are inspected on a risk-based schedule; and
• may compound certain products without patient-specific prescriptions if they satisfy section 503B’s conditions.^[2]

But registration is not a quality trophy that permanently settles the issue. FDA says inspections are a snapshot, facilities under common ownership are evaluated separately, and purchasers should identify the specific facility that made the drug.^[2]

The phrases to stop accepting

The wording is not cosmetic. Each phrase below takes a real regulatory fact — registration, inspection, an ingredient, or another product’s approval — and lets the listener infer approval of the finished pellet. The accurate version preserves the real fact without giving it a power it does not have.

What you may hear	What is wrong with it	The accurate version
“FDA-approved facility”	FDA approves drug products, not a clinic’s marketing phrase for a compounder	“FDA-registered 503B outsourcing facility”
“FDA-certified 503B”	FDA registration is not certification	“Registered with FDA under section 503B”
“Partially FDA approved”	There is no partial-approval category for this method	Identify the exact approved product, application, and labeled use — or say the finished product is compounded
“Made with FDA-approved ingredients”	Approval of another product or ingredient does not transfer to the finished pellet	State the exact finished product’s approval status
“FDA inspected, so it is FDA approved”	Inspection and product approval are different regulatory actions	Name the facility, inspection date, classification, and finished-product status separately

The FDA’s default is also clear: when an available FDA-approved drug can meet the patient’s need, the agency recommends the approved drug rather than a compounded one.^[2]

You now know more than the badge tells you. The next useful question is not “Is the facility impressive?” It is “Which legal facility made my exact pellet, and what does its current record show?”

Get your personalized starting-point plan with Find My HRT Path →

---

Who says SottoPelle is FDA approved — and who does not?

The false approval claim is live on clinic websites, but the current SottoPelle pages we checked do not call the finished pellets FDA approved. The older SottoPelle blog still uses “FDA certified 503B,” which is also inaccurate and should not be repeated.

The claim audit

The quotations below were live when checked on August 25, 2026. They document the language a patient may encounter, who published it, and exactly why it fails. They are not medical evidence, and they do not imply that every SottoPelle clinic uses the same wording.

Publisher	Published wording	Audit verdict
East Lakeland OB-GYN Associates	“only FDA-approved pellets for our SottoPelle Hormone Treatment”	Incorrect. The compounded finished SottoPelle pellets are not FDA approved.[22]
Allure Medical	“FDA-approved branded pellets from companies like SottoPelle and BioTE Medical”	Incorrect. SottoPelle and Biote are not FDA-approved finished pellet brands for menopause.[23]
Vibrant Life	SottoPelle uses approved medications while the methodology has “partial FDA approval”	Incorrect category. A product, route, and use must be identified; “partial FDA approval” is not the status of the SottoPelle Method.[24]
Health Link Medical Group	Pellet HRT is “the safest and most effective” method, and the page tells patients to ask whether pellets come from an “FDA certified 503B facility”	Unsupported superiority claim plus a false regulatory label. FDA registers outsourcing facilities; it does not certify them, and registration does not prove clinical superiority.[25]
Older SottoPelle-domain article	“FDA certified 503B facility”	Wrong word on SottoPelle’s own domain. FDA registers outsourcing facilities; it does not certify them.[13]

The finding that changes what you should do

We checked SottoPelle’s current patient page, provider-training page, pricing page, and Standard of Care PDF for the finished-product approval claim. We did not find it there.

That does not clear every SottoPelle statement. The Standard of Care makes broad safety and superiority claims, and the current patient site makes claims about “natural” hormones and outcomes that are not FDA approval evidence.^[12][9]

But it locates the approval problem more precisely: a local clinic may be adding regulatory language that the core current SottoPelle materials do not use.

That means the clinic has to answer for it. Ask:

Which exact finished product are you calling FDA approved? Please show me its FDA application number and current prescribing information.

If the answer changes to “the pharmacy is registered,” “the ingredients are approved,” or “it is like Testopel,” you have your answer.

What SottoPelle gets credit for

SottoPelle’s Standard of Care requires laboratory work before treatment and at set intervals for baseline evaluation, dosing, continuity, and monitoring. That is a meaningful written expectation, and a clinic that ignores it is not following the protocol SottoPelle itself publishes.^[12]

The same document makes claims that go much further than its cited proof, including broad statements that the hormones are safe, pellets carry less risk, the dose is precise, and the guesswork is eliminated. A dosing tool can support a clinician’s process. It does not establish that an individual dose is safe, optimal, or superior, and ACOG says evidence for custom-compounded menopausal hormone therapy remains insufficient.^[16]

One voice from the other side

A SottoPelle-certified clinician testimonial on the company’s current training page says that “nothing has come close to revolutionizing” his clinical approach.^[10]

Label: provider testimonial published by SottoPelle. It is attributable and was live on August 25, 2026. It is not independent evidence of safety, effectiveness, typical results, or the quality of another clinic.

That is the fair way to use it: as evidence that some clinicians believe deeply in the method — not as proof that the method cleared FDA review.

---

Who actually makes a SottoPelle pellet?

The SottoPelle name does not identify one universal manufacturer. Its current provider page gives certified clinicians the “freedom to select your pellet provider” and lists access to “503B outsourcing facilities,” plural, so the exact compounder, formulation, strength, and lot can differ by clinic.^[10]

This is the most useful finding on the page.

SottoPelle’s public materials describe a network and supplier relationships. They do not give a patient one legal manufacturer name that applies to every insertion. That means a directory search, a certificate on the wall, or the SottoPelle logo cannot tell you:

• which facility compounded your pellet;
• whether that facility is currently registered;
• when it was last inspected;
• whether FDA issued a Form 483, warning letter, recall, or other action relevant to that facility;
• which hormone and milligram dose are in your pellet; or
• which lot number belongs in your medical record.

None of that proves the supplier is bad. Opacity is not proof of poor quality. It is proof that you still have work to do.

For contrast, Biote’s public-company filings identify primary outsourcing facilities, which is one reason its supply-chain events are easier to trace.^[15] That transparency can make the more transparent company look worse. It is still better for the patient than not knowing whom to look up.

The one sentence to use at the clinic is:

Please give me the legal name and address of the facility that made my exact pellets, the hormone and dose in milligrams, and the lot number that will appear in my record.

Then match the legal name and address against FDA’s registered outsourcing-facility list. Registration confirms registration — not product approval — but it gives you the right facility record to investigate.

---

What should you ask before paying a SottoPelle clinic?

Six written answers expose nearly every important gap: manufacturer, dose, approval status, reversibility, uterine protection, and full-year cost. Together, they turn a brand promise into a product and care plan you can verify. A strong clinic will already have the answers in its consent, prescription, label, and aftercare process.

Print or save this table. Do not pay until the blanks are filled.

Ask this	A strong answer sounds like	A concerning answer sounds like
1. Which legal pharmacy or 503B facility makes the exact pellets you will implant in me?	A specific legal name, address, and current registration status, plus the lot record	“Our supplier is FDA approved” with no legal name
2. What hormone, formulation, and dose in milligrams are you prescribing?	A number for estradiol and/or testosterone, not just a pellet count	“Two pellets” or “the standard female dose”
3. Is this finished product FDA approved for this use?	“No, it is compounded,” followed by a clear explanation	“Yes,” “partially,” “the ingredients are,” or “the facility is”
4. What is the written plan if the dose feels too high, I have side effects, or I want it removed?	Who evaluates you, what can be monitored or treated, whether removal is feasible, who would perform it, and what it costs	“That does not happen” or “we will fix it next time”
5. I do or do not have a uterus. What is my endometrial-protection and unexpected-bleeding plan if I receive systemic estrogen?	A specific clinician-led plan, including duration and what triggers evaluation	No separate plan, or “bioidentical means you do not need one”
6. What is my itemized first-year cost?	Consultation, baseline and follow-up labs, pellet drug, insertion, other prescriptions, follow-ups, boosters, complication visits, and expected reinsertion frequency	One per-insertion number presented as the whole cost

Two additions make this even stronger:

• Ask how the clinic records and communicates recalls or safety notices by lot.
• Verify the prescriber’s active license and disciplinary record directly with the state board. SottoPelle’s own terms say its directory does not do that verification for you.^[14]

Micro-commitment: copy question 1 into your phone now. If the clinic cannot name the compounder before insertion, nothing else on the sales page can make up for that.

---

Is Testopel the same as SottoPelle?

No. Testopel is a specific FDA-approved 75 mg testosterone pellet with an approved ANDA, current prescribing information for specified male conditions, and Schedule III controlled-substance status. SottoPelle’s current materials describe custom-compounded pellets supplied through provider-selected compounders; Testopel’s approval does not transfer to those products or to use in menopausal women.^[7]

Decision fact	Testopel	A custom-compounded SottoPelle pellet
FDA-approved finished product?	Yes	No
Application	ANDA 080911	No approved NDA or ANDA for the finished compounded pellet
Strength	Fixed 75 mg testosterone pellet	Clinic-prescribed strength and formulation; verify in milligrams
Hormones	Testosterone	May include testosterone, estradiol, or both, depending on the prescription
Current labeled population	Specified male hypogonadism indications; delayed puberty in carefully selected males	No FDA-approved label for the finished compounded product
Use in women	Would be off-label; there is no FDA-approved testosterone product for women in the United States	Compounded and not FDA approved
Controlled substance	Schedule III	Testosterone is Schedule III; a compounded testosterone pellet still requires a valid prescription[8]
Dose flexibility after insertion	Label describes pellet dosing as less flexible than other testosterone routes	Not readily titratable after insertion; clinic-specific removal plan must be discussed

Two distinctions matter:

Approved product is not the same as approved use. A clinician may prescribe an approved drug off-label, but off-label use does not become FDA-approved use. A patient should be told the exact product and that its use in a woman is off-label.

Compounded product is not an approved generic. FDA distinguishes compounded drugs from approved generics. Calling a custom pellet “basically Testopel” skips the formulation, strength, manufacturer, approval, and labeled-use differences.^[1]

And because testosterone is Schedule III, no clinic should describe it as a casual wellness add-on. It requires a prescription, controlled-substance handling, and an individualized medical decision.^[7][8]

---

Does an NDC number or DailyMed listing prove approval?

No. FDA says an NDC is a product identifier and that assignment or inclusion in the NDC Directory does not denote approval. DailyMed is useful for reading submitted labeling, but the existence of a page there is not a substitute for confirming an approved NDA or ANDA in an FDA approval database.^[3][4][5]

Three things can look official without proving approval:

• An NDC number. The directory contains both approved and unapproved products.
• A DailyMed record. DailyMed publishes labeling records; use Drugs@FDA or the Orange Book to confirm an approved application.
• A certificate of analysis. It can provide useful batch-test information, but it is not an FDA approval decision.

The lookup sequence that works

1. Get the exact product name, NDC if one exists, legal manufacturer or compounder, strength, and package label.
2. Search the FDA NDC Directory.
3. Read the marketing category instead of stopping at the fact that a record exists.
4. Check Drugs@FDA or the Orange Book for an approved NDA or ANDA.
5. Match the product, strength, dosage form, application holder, and intended use. Do not transfer approval from a different product.

For outsourcing-facility products, the NDC data may identify the marketing category “Outsourcing Facility Compounded Human Drug Product (Exempt From Approval Requirements).” That field is useful because it tells you what regulatory pathway the listing claims. It still does not prove that the product is approved, safe for you, or made by the facility your clinic named.^[6]

One field can end the argument. It cannot replace the rest of the treatment decision.

---

If SottoPelle is not FDA approved, is it legal and is it safe?

Legal, approved, and well supported are three separate questions. Compounded hormone pellets can be lawfully prescribed and prepared when federal and state requirements are met, but they are not FDA-approved finished drugs, and professional guidance does not treat routine compounded pellet use as equivalent to approved menopause therapy.^[1][16]

1. Can the product be lawfully prescribed and compounded? Potentially yes, under the applicable compounding pathway and state law.
2. Did FDA approve this finished product for this use? No.
3. Does the evidence establish that it is the best or safest route for this woman? No universal answer; the evidence and professional recommendations have important limits.

Clinic marketing often answers the first question and lets the patient assume it answered the other two. Critics sometimes answer the second question and imply the first answer is “no.” Both shortcuts fail the woman trying to make a real decision.

When compounding can serve a real need

FDA gives straightforward examples: an approved medicine may be medically inappropriate because a patient is allergic to a dye or needs a dosage form that is not commercially available. In those situations, compounding can solve an actual treatment problem.^[1]

ACOG makes the same distinction. It recognizes that compounding can be appropriate in some circumstances while recommending approved menopausal hormone therapies over custom-compounded products when approved formulations can meet the need.^[16]

The testosterone gap deserves separate treatment. There is no FDA-approved testosterone product for women in the United States. ACOG says that when compounded testosterone is considered, clinician and patient should use shared decision-making — and ACOG recommends a preparation other than a pellet because of limited safety data and the inability to readily remove the dose.^[16]

So compounding is not automatically a loophole. Sometimes it is the only available route to a clinically considered formulation. The question is whether the need is real, the dose and compounder are transparent, the route fits the woman’s priorities, and the follow-up plan survives the possibility that the first dose is wrong.

---

What does the evidence actually show about hormone pellets?

The strongest honest conclusion is not “pellets are poison” or “pellets are proven superior.” ACOG recommends against routine custom-compounded menopausal therapy when approved options exist and recommends non-pellet testosterone preparations; observational studies report both symptom benefit and meaningful safety concerns, but the evidence is not a SottoPelle-specific randomized comparison.^[16]

The case for caution

ACOG Clinical Consensus No. 6, reaffirmed in 2026, says there is a lack of high-quality safety and efficacy data for custom-compounded menopausal hormone therapy. It recommends preparations other than pellets for testosterone because of limited safety data and the inability to remove the pellet.^[16]

That wording is often simplified into “pellets can never be removed.” The more accurate practical point is:

A pellet is not readily titratable, and removal is not the simple routine equivalent of peeling off a patch or stopping a pill.

Removal may be difficult, may require another procedure, and may not be feasible depending on the implant’s location and the clinic’s capabilities. That is why question 4 belongs in writing before insertion.

The Wheatley estradiol-implant audit reviewed 114 postmenopausal women who received 50 mg estradiol implants. Among the 92 who had more than one implant, the estimated median time for estradiol to return to baseline was 311 days, with a range of 108 to 1,228 days. The authors stressed prolonged action, difficult removal, careful patient selection, and continued progestogen after stopping implants for women with a uterus.^[26]

That study was not SottoPelle-specific, and it does not tell us that every modern pellet lasts 311 days. It proves a narrower point that matters: the biological exposure can outlast the reinsertion schedule or the patient’s assumption that the pellet is “finished.”

The Jiang retrospective study compared 384 postmenopausal women receiving compounded pellets with 155 receiving FDA-approved hormone therapy. It reported documented side effects in 57.6% of the pellet group versus 14.8% of the approved-product group, with mean peak estradiol of about 237.7 pg/mL versus 93.5 pg/mL and mean peak testosterone of about 194.0 ng/dL versus 15.6 ng/dL.^[27]

Those are striking numbers, but they are not a clean SottoPelle-versus-patch trial. The groups were not randomized, the regimens differed substantially, and testosterone exposure was far more common in the pellet group. The study supports concern about dosing and adverse effects. It does not establish that every pellet patient will reproduce those outcomes or that the brand name caused them.

The case supporters make

Pellet supporters value long dosing intervals, no daily application, and avoidance of first-pass liver metabolism. Some women report meaningful symptom relief, and observational studies and pharmacokinetic work show that implants can maintain hormone exposure over months.^[28][29]

A 2025 narrative review argues that estradiol pellets may have a selective role for women with poor transdermal absorption, adherence barriers, or particular clinical circumstances. The same literature base still lacks large, long-term, head-to-head randomized trials that establish SottoPelle-specific superiority over approved routes.^[28]

That is the fair pro-pellet position: there may be women for whom the convenience and sustained exposure solve a real problem. It is not “pellets are the safest and most effective method available,” and it is not permission to hide the nonapproval or reversibility tradeoff.

The correction almost nobody publishes: 4,202 is not 4,202 proven pellet injuries

In 2019, FDA said an inspection of BioTE Medical uncovered information about 4,202 adverse events that had not been reported to the agency during 2013–2018. Because critical information was missing, FDA said it could attribute only 61 reports — with pellet extrusion and cellulitis given as examples — to compounded testosterone pellets.^[30]

Four thousand two hundred was the number of unreported records. It was not the number of proven pellet injuries.

That correction runs in the pellet industry’s favor, and it belongs here.

Two facts still remain:

• the reporting failure was real; and
• the incident involved BioTE and pellets made by named compounders, not SottoPelle.

The right lesson is not to transfer the event to SottoPelle. It is to ask every clinic how it records adverse events, identifies the compounder and lot, and notifies patients about recalls or safety actions.

Uterus status is not a footnote

A woman with a uterus who receives systemic estrogen needs a clear plan for protecting the endometrium. “The pellet is bioidentical” is not that plan.

Ask which progestogen is prescribed, by which route, at what dose and schedule, how long it continues after the final pellet, and how unexpected bleeding is handled. The Menopause Society warns that inadequate progesterone in a compounded plan can leave the uterine lining unprotected.^[17]

If the clinic cannot answer that before insertion, it is not ready to insert systemic estrogen.

---

Did the 2026 FDA hormone-label changes approve SottoPelle?

No. On February 12, 2026, FDA approved revised prescribing information for six FDA-approved menopausal hormone therapy products; compounded pellets have no FDA-approved label to revise, so the action did not approve SottoPelle or change its regulatory category.^[31][32]

The dated sequence is:

• July 17, 2025: FDA convened an expert panel on menopausal hormone therapy.
• November 10, 2025: FDA requested labeling changes from manufacturers.
• February 12, 2026: FDA approved the first six revised labels after 29 companies submitted proposed changes.^[31]

The six products in the first batch were Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.^[32]

FDA removed cardiovascular disease, breast cancer, and probable dementia language from the boxed warning for those products while retaining risk information elsewhere in prescribing information as appropriate. The endometrial-cancer boxed warning remains relevant to systemic estrogen-alone products for women with a uterus.^[31]

What this means for the pellet question:

• it did not add a new SottoPelle application;
• it did not create an approved estradiol pellet for menopause;
• it did not approve compounded testosterone for women; and
• it did not make a registered 503B facility an approved-drug manufacturer for every product it compounds.

The approved products received updated approved labels. The compounded pellet still has no FDA-approved label.

Removing a dementia warning is not approval to market hormone pellets for dementia, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, or cognitive enhancement. No SottoPelle pellet carries FDA approval for those neurological uses.

---

Does insurance cover SottoPelle?

There is no national yes-or-no answer. Coverage depends on the exact product, diagnosis, plan, network, and billing, and payer policies often separate compounded menopause pellets from FDA-approved Testopel coverage for specified indications.^[33]

A blanket “almost never” sounds useful but is too broad. Aetna’s current policy is a clean example of why: it lists CPT 11980 as potentially covered for testosterone when criteria are met, but not for estradiol. Other plans and state programs apply their own definitions and exclusions.^[33]

The code to ask about

CPT 11980 is the insertion procedure code used for subcutaneous hormone pellets. It is only one part of the bill.

Ask the insurer and clinic to separate:

1. the consultation;
2. baseline and follow-up laboratory work;
3. the pellet drug itself;
4. CPT 11980 for insertion;
5. any other prescriptions, including progestogen;
6. follow-up or complication visits; and
7. removal, if attempted.

A benefit quote is not a guarantee of payment, but it is more useful than asking, “Do you cover SottoPelle?” The brand may not appear anywhere in the plan’s system.

Use this script:

Is the exact compounded pellet covered? Is CPT 11980 covered for my diagnosis and sex? Are the clinician, facility, and lab in network? What authorization, deductible, and coinsurance rules apply?

What SottoPelle costs

SottoPelle does not publish a national patient price, and certified clinics set their own fees and inclusions. A single clinic’s number is a local quote, not “the SottoPelle price.”

Do not let a per-insertion number stand in for a year of care. Ask for an itemized 12-month estimate showing the expected number of insertions, consultation, labs, follow-ups, other prescriptions, memberships, boosters, and aftercare.

For a dated multi-clinic dataset and calculator, use our separate hormone pellet therapy cost guide. Keeping the live dataset there avoids turning this FDA-status page into a stale, duplicated price page.

---

Does leaving pellets automatically mean choosing only FDA-approved care?

No. Some telehealth providers The HRT Index may earn from also prescribe compounded medication. “Leave pellets for telehealth” is not automatically a clean FDA-approved answer, and pretending otherwise would repeat the exact blur this page is correcting.

Midi Health is the clearest example. Midi says its testosterone for women is compounded and not FDA approved, and it does not prescribe testosterone pellets. Its testosterone program is currently available in 25 states. Current self-pay visit prices are $250 for an initial visit and $150 for follow-up; Midi says it is in network with most PPO plans, Medicare is out of network, and it cannot accept Medicaid or Medi-Cal patients.^[34][35]

If your rule is “no compounded medication at all,” Midi is not a clean testosterone answer.

The meaningful distinction is route and dose control:

• future topical applications can be paused or changed without another insertion;
• a pellet continues releasing after it is placed and is not readily titratable; and
• Midi also prescribes FDA-approved estradiol and progesterone products when clinically appropriate, but the exact prescription must be verified rather than assumed.^[34][36]

That is a damaging admission we are not going to hide. Same nonapproval category for the compounded testosterone. Very different reversibility.

The page’s safest conversion is therefore not a provider button. It is a route decision:

Compare your adjustable, FDA-approved, compounded, insurance, and in-person starting points with Find My HRT Path →

The tool keeps approved and compounded options visibly separate and flags when online care is not the right starting point. No provider can make the medical decision from a quiz; a licensed clinician still has to evaluate and prescribe.

---

Will compounded hormone pellets be banned?

We found no current FDA rule or scheduled federal action banning compounded hormone pellets as of August 25, 2026. The National Academies recommended that FDA review several hormones and compounded hormone pellets for possible placement on the Difficult to Compound List, but a recommendation for review is not a ban or a final FDA rule.^[37]

The Difficult to Compound List matters because drugs placed there may not qualify for compounding exemptions. But legal status changes only through the required FDA process — not because a clinic, critic, or sales page says a ban is coming.

What we verified:

• FDA’s Pharmacy Compounding Advisory Committee met July 23–24, 2026 to discuss seven peptide-related bulk substances, not compounded hormone pellets.^[38]
• FDA says it will hold another Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to discuss five peptide-related bulk substances — Cathelicidin (LL-37), GHK-Cu, dihexa acetate, melanotan II, and pegylated mechano growth factor — not compounded hormone pellets.^[39]
• We found no current FDA rulemaking notice that schedules a ban on compounded hormone pellets.

What is happening on September 17, 2026

FDA’s Office of Women’s Health and Center for Drug Evaluation and Research are holding a public workshop titled “Testosterone Use in Menopausal Women.” The purpose is to examine evidence, knowledge gaps, long-term safety, study design, and potential drug development for women.^[40]

That is not an approval hearing and not a ban announcement. It is FDA formally examining the gap that leaves women without an approved testosterone product.

No manufactured urgency. If future regulatory change matters to your plan, ask the clinic what happens to refills, records, pharmacy supply, and follow-up if the legal or supplier landscape changes.

---

What FDA-approved alternatives can you discuss instead?

FDA-approved estradiol and progesterone products exist as patches, gels, sprays, tablets, capsules, creams, inserts, and rings. They are not interchangeable with a pellet, and the correct route depends on symptoms and history, but they give many women an approved option whose next dose can be changed or withheld without another implant procedure.^[20]

What you are trying to solve	Route to discuss with a clinician	FDA status	Dose-control difference
Systemic hot flashes or night sweats with transdermal estrogen	Estradiol patch, gel, or spray	FDA-approved products exist	A clinician can change the next dose; a patch can be removed
Systemic symptoms when an oral route is appropriate	FDA-approved oral estrogen product	FDA-approved products exist	The next tablet can be withheld under the treatment plan
Vaginal dryness, painful sex, or urinary symptoms without a need for whole-body therapy	Local vaginal estradiol cream, insert, or ring	FDA-approved products exist	Local treatment can be adjusted without a pellet procedure
Endometrial protection with systemic estrogen in a woman with a uterus	FDA-approved progestogen options, including oral micronized progesterone where appropriate	FDA-approved products exist	Schedule and dose can be changed by the prescriber
Testosterone for a postmenopausal woman with a properly assessed indication	No FDA-approved U.S. product for women	Use in women is either off-label use of an approved male product or use of an unapproved compounded product	Professional guidance favors physiologic dosing and recommends against pellet preparations that cannot be readily adjusted

“Bioidentical” does not divide approved from compounded. FDA-approved estradiol and micronized progesterone products can be bioidentical in molecular structure. Custom compounding is not required for a hormone to be bioidentical.^[17]

The column that matters: can the next dose be stopped or changed?

For a tablet, cream, gel, spray, or patch, the prescriber can change what happens next without another procedure. That does not promise that hormone levels or side effects disappear instantly. It means the patient and clinician can stop adding more exposure immediately.

For a pellet, the current insertion remains active. The global consensus recommends stopping testosterone if there is no meaningful benefit by six months; a route that cannot be stopped on demand makes that exit plan more complicated.^[21]

Convenience is a real benefit. Reversibility is a real benefit. You are allowed to decide which one matters more — after the clinic gives you the truth about both.

Who should leave this page for a more specific answer?

• You already tried approved patches, gels, or pills and could not absorb or tolerate them. Pellets may remain a legitimate discussion. Take the six questions with you.
• You want to compare SottoPelle with Biote. Compare the exact clinic, legal compounder, lot traceability, dose, follow-up, and written year-one cost; neither brand turns a compounded pellet into an FDA-approved product.
• You want testosterone specifically. Compare route, prescription, monitoring, FDA status, and Schedule III requirements before choosing a cream, gel, injection, or pellet.
• Your main problem is vaginal dryness, painful sex, or urinary symptoms. You may not need systemic therapy. Start with our vaginal estrogen guide.
• You have unexplained bleeding, a complex cancer or clotting history, severe symptoms, or a situation that needs examination. Start in person.

---

You already have pellets in. What now?

The fact that a pellet is not FDA approved is not, by itself, an emergency or proof that it must be removed. The useful next steps are to identify exactly what was inserted, preserve the manufacturer and lot record, follow the prescribed monitoring plan, and contact a clinician promptly about concerning symptoms.

Take a breath. You made a decision with the information you had. This page is here to make the next decision clearer, not to punish the last one.

1. Get the record. Ask for the insertion date, hormone, dose in milligrams, compounder’s legal name and address, lot number, procedure note, and consent form.
2. Do not treat the quoted reinsertion interval as proof that exposure has ended. Estradiol implants have shown prolonged release in published audits, and individual duration varies.^[26]
3. If you have a uterus and received systemic estrogen, do not stop a prescribed progestogen based only on the belief that the pellet has worn off. Ask the prescriber for a specific endometrial-protection plan.^[17][26]
4. Track symptoms simply. Bleeding, acne, hair changes, mood, sleep, headaches, breast symptoms, insertion-site changes, and anything that feels new or severe.
5. Arrange an independent second opinion if the clinic will not answer basic product or dose questions. A gynecologist, menopause-trained clinician, or other qualified prescriber can review the record and your current symptoms.

Any unexplained bleeding after menopause deserves prompt medical evaluation.^[18] Seek urgent or emergency care for chest pain, sudden shortness of breath, one-sided leg swelling or pain, sudden severe headache, vision or neurologic changes, heavy bleeding, or signs of a serious insertion-site infection.^[19] This list is not exhaustive; use emergency services when symptoms feel severe or rapidly worsening.

The point is not panic. It is traceability, follow-up, and a plan that does not disappear after the payment clears.

---

Frequently asked questions

These are the follow-up questions most likely to send a reader back to search. Each answer keeps the product, facility, ingredient, and intended use separate.

Is SottoPelle FDA approved?

No. The custom-compounded estradiol and/or testosterone pellets used through SottoPelle-certified clinics are not FDA-approved finished products. Current core SottoPelle pages we reviewed did not call the finished pellets approved, although an older SottoPelle article inaccurately called a 503B facility “FDA certified.”

Are SottoPelle pellets safe?

There is no FDA premarket review of the finished compounded pellets, and we found no SottoPelle-specific randomized trial establishing overall safety or superiority. ACOG recommends approved menopausal hormone therapies when they can meet the need and recommends non-pellet preparations for testosterone because of limited safety data and difficult reversibility.

Is SottoPelle legal?

Compounded medicines can be lawfully prescribed and prepared under federal and state compounding rules. Legal and FDA approved are different statuses.

Is Biote FDA approved?

Biote’s custom-compounded menopause pellets are not FDA-approved finished drugs. Biote and SottoPelle differ in training, software, supply-chain disclosure, clinic networks, and commercial structure — not in a blanket approval category for their compounded pellets.

Are bioidentical hormones FDA approved?

Some are. FDA-approved estradiol and micronized progesterone products can be bioidentical; compounded products are not FDA approved. “Bioidentical” describes molecular structure, while “FDA approved” describes the status of a specific finished product for a specific use.

What is the FDA-approved testosterone pellet?

Testopel is a 75 mg FDA-approved testosterone pellet with specified male indications. It is Schedule III and prescription-only. Its approval does not extend to SottoPelle, estradiol pellets, or testosterone-pellet use in menopausal women.

Can hormone pellets be removed?

Removal may sometimes be attempted surgically, but it is not routine, may be difficult, and is not equivalent to removing a patch. Ask the clinic who can perform removal, when it is feasible, what risks and costs apply, and what the plan is when removal is not practical.

How long do hormone pellets stay in your system?

It varies by hormone, dose, product, and patient. In one audit of 50 mg estradiol implants, the estimated median return to baseline after more than one implant was 311 days, with a range of 108 to 1,228 days. That study was not SottoPelle-specific, but it shows why a reinsertion schedule is not a precise off-switch.

Does insurance cover SottoPelle?

Coverage is plan-specific and often split among the drug, insertion, visits, and labs. Some plans may cover CPT 11980 or Testopel under narrow criteria that do not apply to a compounded estradiol or women’s menopause pellet; get an itemized benefit check before relying on coverage.

Does an NDC number mean the pellet is approved?

No. FDA says an NDC does not denote approval. Use the NDC record to identify the product, then confirm an approved NDA or ANDA in Drugs@FDA or the Orange Book.

Is a 503B facility FDA approved?

No. A facility can be registered with FDA as an outsourcing facility and subject to CGMP, adverse-event reporting, and risk-based inspection. Its compounded drugs remain unapproved, and registration does not prove current compliance.

Will compounded hormone pellets be banned?

We found no current FDA rule or scheduled federal action banning compounded hormone pellets. The National Academies recommended FDA review of compounded hormone pellets for possible regulatory restrictions, but that recommendation has not become a ban. Check current FDA rulemaking rather than relying on sales urgency or social-media claims.

What is the single most important question to ask a clinic?

“Which legal facility made the exact pellet you plan to implant, and what hormone, milligram dose, and lot number will appear in my record?” That answer gives you something real to verify.

---

How did The HRT Index research and verify this page?

This page was produced under The HRT Index Verification Standard: read every published commercial fact used, separate FDA-approved from compounded products, verify changing facts against current sources, label what remains unknown, and re-check on a fixed schedule. The framework uses five pillars in this order: clinical legitimacy, care quality, medication fit, price transparency, access. It is not a numeric score.

For this page, we:

• read SottoPelle’s current patient, provider, pricing, terms, and Standard of Care materials;
• searched those core materials for FDA-approval language and separately documented an older SottoPelle-domain 503B wording error;
• checked every regulatory conclusion against FDA pages or an approved label;
• used ACOG and The Menopause Society for professional guidance;
• used clinic pages only to document what those clinics publicly claimed;
• separated the 4,202 unreported adverse-event records from the 61 reports FDA could attribute;
• preserved limitations of the pellet studies instead of turning observational data into a brand verdict;
• did not publish a national SottoPelle price or insurance verdict where current evidence could not support one; and
• dated the commercial and regulatory checks.

Our editorial conclusion: for most women who have not yet tried an appropriate FDA-approved route, an approved and adjustable option is the stronger starting comparison. The biggest reason is not that every pellet is dangerous. It is that the exact compounded product lacks FDA approval and the dose cannot be readily changed after insertion.

If approved routes have genuinely failed, a pellet can remain a legitimate conversation — with a clinician who names the compounder, explains the dose, protects the endometrium when needed, gives a real aftercare plan, and answers all six questions in writing.

We earn nothing from SottoPelle, Biote, Testopel, or the clinics quoted in the claim audit. See our affiliate disclosure, editorial standards, and corrections policy. Found an error? Tell us, and we will correct it and date the change.

Last verified: August 2026. We re-check SottoPelle’s public wording and the clinic-claim audit monthly; provider pricing and insurance facts before any commercial update; and FDA status, labels, payer policies, and compounding actions quarterly or whenever a material change is announced.

---

Still not sure which HRT program is right for you? Use Find My HRT Path.

It takes about 90 seconds, requires no email or account, keeps FDA-approved and compounded options clearly labeled, and flags when online care is not the right starting point.

---

Sources

¹ U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed August 25, 2026.

² U.S. Food and Drug Administration. Questions and Answers: Outsourcing Facility Registration. Accessed August 25, 2026.

³ U.S. Food and Drug Administration. National Drug Code Directory. Accessed August 25, 2026.

⁴ National Library of Medicine. About DailyMed. Accessed August 25, 2026.

⁵ U.S. Food and Drug Administration. FDA’s Labeling Resources for Human Prescription Drugs. Accessed August 25, 2026.

⁶ U.S. Food and Drug Administration. Structured Product Labeling: Marketing Category. Accessed August 25, 2026.

⁷ DailyMed. Testopel — testosterone pellet, current prescribing information. Updated July 17, 2025; accessed August 25, 2026.

⁸ Electronic Code of Federal Regulations. 21 CFR § 1308.13 — Schedule III. Current through August 25, 2026.

⁹ SottoPelle. What Is Bioidentical Hormone Replacement Therapy?. Accessed August 25, 2026.

¹⁰ SottoPelle. Hormone Replacement Therapy Courses for Physicians. Accessed August 25, 2026.

¹¹ SottoPelle. BHRT Programs and Pricing for Providers. Accessed August 25, 2026.

¹² SottoPelle. SottoPelle Standard of Care. Accessed August 25, 2026.

¹³ SottoPelle. Why Hormone Pellets Are the Best Choice. Accessed August 25, 2026.

¹⁴ SottoPelle. Terms of Use. Accessed August 25, 2026.

¹⁵ biote Corp. Annual Report on Form 10-K for the year ended December 31, 2025. Filed 2026; accessed August 25, 2026.

¹⁶ American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy, Clinical Consensus No. 6. November 2023; reaffirmed 2026.

¹⁷ The Menopause Society. Menopause Topics: Hormone Therapy. Accessed August 25, 2026.

¹⁸ American College of Obstetricians and Gynecologists. ACOG Publishes Updated Guidance on Evaluation of Postmenopausal Bleeding. April 2026.

¹⁹ National Library of Medicine. Estrogen and Progestin (Hormone Replacement Therapy). Updated May 15, 2026.

²⁰ U.S. Food and Drug Administration. Menopause: Medicines to Help You. Accessed August 25, 2026.

²¹ Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. 2019;104(10):4660–4666.

²² East Lakeland OB-GYN Associates. SottoPelle Hormone. Accessed August 25, 2026.

²³ Allure Medical. Are Hormone Pellets as Safe as They Seem?. Accessed August 25, 2026.

²⁴ Vibrant Life. The Benefits of Hormone Pellet Therapy. Accessed August 25, 2026.

²⁵ Health Link Medical Group. Hormone Replacement Therapy. Accessed August 25, 2026.

²⁶ Wheatley S, Bell RJ, Stuckey BGA, Robinson PJ, Davis SR. Clinical audit of estradiol implant therapy: Long duration of action and implications in non-hysterectomised women. Maturitas. 2016;94:84–86.

²⁷ Jiang X, et al. Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women. Menopause. 2021.

²⁸ Subcutaneous Estradiol Pellets as Hormone Therapy in Menopause. Journal of Clinical Medicine. 2025.

²⁹ Pharmacokinetic analysis of 25 mg estradiol subcutaneous implants in postmenopausal women. 2025.

³⁰ U.S. Food and Drug Administration. Statement on improving adverse event reporting of compounded drugs to protect patients. September 9, 2019.

³¹ U.S. Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.

³² U.S. Food and Drug Administration. Menopausal Hormone Therapies with Updated Prescribing Information. Accessed August 25, 2026.

³³ Aetna. Implantable Hormone Pellets, Clinical Policy Bulletin 0345. Accessed August 25, 2026.

³⁴ Midi Health. Testosterone for Women and Testosterone for Menopause. Accessed August 25, 2026.

³⁵ Midi Health. Pricing and Insurance. Accessed August 25, 2026.

³⁶ Midi Health. Bioidentical Hormone Therapy. Accessed August 25, 2026.

³⁷ National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy. 2020.

³⁸ U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Accessed August 25, 2026.

³⁹ U.S. Food and Drug Administration. Meeting of the Pharmacy Compounding Advisory Committee. Accessed August 25, 2026.

⁴⁰ U.S. Food and Drug Administration. Testosterone Use in Menopausal Women; Public Workshop. Federal Register. August 18, 2026.